Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | GFER | P55789 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | RAD52 | P43351 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23544863 | 0.86 | MAPT (0.46) | MAPTKDM4EGFERGAASMN1; SMN2 | |
| SCHEMBL81372 | 0.84 | MAPT (0.47) | MAPTKDM4EGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL1048101 | 0.84 | MAPT (0.61) | MAPTKDM4EGFERGAASMN1; SMN2 | |
| SCHEMBL28335402 | 0.83 | MAPT (0.51) | MAPTKDM4EGFERGAASMN1; SMN2 | |
| SCHEMBL10269322 | 0.82 | CHRNA7 (0.56) | KDM4EGFERRAD52ALDH1A1ADRA2C | |
| SCHEMBL1991688 | 0.82 | MAPT (0.50) | MAPTKDM4EGFERGAASMN1; SMN2 | |
| SCHEMBL188924 | 0.82 | MAPT (0.67) | MAPTKDM4EGFERGAASMN1; SMN2 | |
| Bromide SCHEMBL11208376 | 0.81 | KDM4E (0.67) | MAPTKDM4EGAASMN1; SMN2RAD52 | |
| SCHEMBL13654227 | 0.80 | MAPT (0.59) | MAPTKDM4ESMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL12386855 | 0.80 | CHRNA7 (0.46) | MAPTKDM4EGFERRAD52ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105670-B2 | Intermediates useful in the preparation of diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-7094896-B2 | Diaminothiazoles having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1358169-B1 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | HOFFMANN LA ROCHE (CH) | 2006-01-11 | — | — | EP | disclosed |
| US-6756374-B2 | CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS | HOFFMANN-LA ROCHE INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | DING QINGJIE (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | DING QINGJIE (US) | 2004-04-29 | — | — | US | disclosed |
| EP-1358169-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CHEN LI (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002057261-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | MAPT 3064/4885KDM4E 973/4885GFER 4289/4885 |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | MAPT 3064/4885KDM4E 973/4885GFER 4289/4885 |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | CDK4, CDK2, CDKL4 | MAPT 2939/4885KDM4E 1021/4885GFER 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.